Meet Our Team
Our experienced leadership team has a deep research focus and leverages diverse perspectives to BioMimetix’s clinical and company development. With a CEO that has over 40 years of experience in developing and discovering metalloporphyrins, the team is passionate about advancing this new drug class to transform the treatment of cancer.Strong, Reseach-Focused Team
James Crapo, MD
CEO
Rob Hellewell
President & Chief Business Officer
David S Silberstein, PhD
VP of R&D
Shayne Gad, PhD
VP of Drug Safety, Regulatory Affairs
Robert Ogden, CPA
CFO
Sara Penchev
Director of Clinical Operations
David MacLeod, PhD
Director of Information Science & Data Management
John Wetzel, PhD
Director, Chemistry, Manufacturing and Controls